2011: PhD in Virology, Paris Diderot University
2009: Pharm. D., University Paris Sud
2008: Master in microbial ecology, physiopathology and treatment, Paris Sud University
1998-2003: Second cycle of pharmaceutical studies, Paris Sud University

2013-present: Hospital Practitioner in Virology, Medical School, Paris Diderot University
2010-2012: Assistant Professor in Virology, Hôpital Bichat-Claude, Medical School, Paris Diderot University
2003-2009: Resident, medical biology and microbiology, AP-HP (Assistance Publique des Hôpitaux de Paris)

Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ACH2C
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.

Sellier P, Maylin S, Amarsy R, Mazeron MC, Larrouy L, Haïm-Boukobza S, Lopes A, Moreno MD, Ricbourg A, Simoneau G, Magnier JD, Mercier-Delarue S, Delcey V, Evans J, Cambau E, Barranger E, Simon F, Bergmann JF
Untreated highly viraemic pregnant women from Asia or sub-Saharan Africa often transmit hepatitis B virus despite serovaccination to newborns.
Liver Int. 2015, 35, 409–416.

Visseaux B, Larrouy L, Calin R, Katlama C, Poynard T, Ratziu V, Thibault V
Anti-hepatitis C virus antibody detection in oral fluid: influence of human immunodeficiency virus co-infection.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2013, 58, 385-390.

Larrouy L, Vivot A, Charpentier C, Bénard A, Visseaux B, Damond F, Matheron S, Chene G, Brun-Vezinet F, Descamps D, ACH2C
Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
AIDS (London, England) 2013, 27, 69-80.

2021

Lebourgeois S, Chenane HR, Houhou-Fidouh N, Menidjel R, Ferré VM, Collin G, Benmalek N, Coppée R, Larrouy L, Yazdanpanah Y, Timsit JF, Charpentier C, Descamps D, Visseaux B
Earlier In Vitro Viral Production With SARS-CoV-2 Alpha Than With Beta, Gamma, B, or A.27 Variants.
Frontiers in Cellular and Infection Microbiology 2021, 11, 792202.

2020

Charpentier C, Ichou H, Damond F, Bouvet E, Chaix ML, Ferré V, Delaugerre C, Mahjoub N, Larrouy L, Le Hingrat Q, Visseaux B, Mackiewicz V, Descamps D, Fidouh-Houhou N
Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott).
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2020, 132, 104618.

Ekouevi DK, Larrouy L, Gbeasor-Komlanvi FA, Mackiewicz V, Tchankoni MK, Bitty-Anderson AM, Gnatou GYS, Sadio A, Salou M, Dagnra CA, Descamps D, Coffie PA
Prevalence of hepatitis B among childbearing women and infant born to HBV-positive mothers in Togo.
BMC infectious diseases 2020, 20, 839.

2019

Nguyen T, Akhavan S, Caby F, Bonyhay L, Larrouy L, Gervais A, Lebray P, Poynard T, Calmus Y, Simon A, Valantin MA, Calvez V, Marcelin AG, Todesco E
Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing.
International Journal of Antimicrobial Agents 2019, 53, 80-83.

2018

Le Hingrat Q, Perrier M, Collin G, Drumard S, Storto A, Bertine M, Larrouy L, Matheron S, Damond F, Charpentier C, Descamps D, Visseaux B
Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads.
Journal of Virological Methods 2018, 257, 12-15.

2017

Wirden M, Larrouy L, Mahjoub N, Todesco E, Damond F, Delagreverie H, Akhavan S, Charpentier C, Chaix ML, Descamps D, Calvez V, Marcelin AG
Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2017, 96, 49-53.

2016

Desnoyer A, Pospai D, Lê MP, Gervais A, Heurgué-Berlot A, Laradi A, Harent S, Pinto A, Salmon D, Hillaire S, Fontaine H, Zucman D, Simonpoli AM, Muret P, Larrouy L, Bernard Chabert B, Descamps D, Yazdanpanah Y, Peytavin G
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.
Journal of Hepatology 2016, 65, 40-47.

Visseaux B, Mortier E, Houhou-Fidouh N, Brichler S, Collin G, Larrouy L, Charpentier C, Descamps D
Zika virus in the female genital tract.
The Lancet. Infectious Diseases 2016, 16, 1220.

2015

Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ACH2C
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.

Sellier P, Maylin S, Amarsy R, Mazeron MC, Larrouy L, Haïm-Boukobza S, Lopes A, Moreno MD, Ricbourg A, Simoneau G, Magnier JD, Mercier-Delarue S, Delcey V, Evans J, Cambau E, Barranger E, Simon F, Bergmann JF
Untreated highly viraemic pregnant women from Asia or sub-Saharan Africa often transmit hepatitis B virus despite serovaccination to newborns.
Liver Int. 2015, 35, 409–416.

2013

Visseaux B, Larrouy L, Calin R, Katlama C, Poynard T, Ratziu V, Thibault V
Anti-hepatitis C virus antibody detection in oral fluid: influence of human immunodeficiency virus co-infection.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2013, 58, 385-390.

Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi F, Yeni P, Descamps D, A1ATSG
Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.
The Journal of Antimicrobial Chemotherapy 2013, 68, 690-696.

Lê MP, Gervais A, Le Beller C, Long K, Larrouy L, Papy E, Mal H, Descamps D, Peytavin G
Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir.
The Journal of Antimicrobial Chemotherapy 2013, 68, 1208-1209.

Charpentier C, Lambert-Niclot S, Visseaux B, Morand-Joubert L, Storto A, Larrouy L, Landman R, Calvez V, Marcelin AG, Descamps D
Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010.
The Journal of Antimicrobial Chemotherapy 2013, 68, 2197-2198.

Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, Mourez T, Collin G, Brun-Vézinet F, Plantier JC, Descamps D
In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
AIDS (London, England) 2013, 27, 2959-2961.

Larrouy L, Vivot A, Charpentier C, Bénard A, Visseaux B, Damond F, Matheron S, Chene G, Brun-Vezinet F, Descamps D, ACH2C
Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
AIDS (London, England) 2013, 27, 69-80.

Visseaux B, Charpentier C, Taieb A, Damond F, Bénard A, Larrouy L, Chêne G, Brun-Vézinet F, Matheron S, Descamps D, ACH2C
Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.
AIDS (London, England) 2013, 27, 292-295.

Charpentier C, Champenois K, Gervais A, Landman R, Joly V, Le Gac S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, Yazdanpanah Y
Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients.
PloS One 2013, 8, e59205.

2012

Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, AC0H2C
Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
The Journal of Infectious Diseases 2012, 205, 111-120.

Charpentier C, Larrouy L, Visseaux B, Landman R, Levittas M, Storto A, Damond F, Yazdanpanah Y, Yeni P, Brun-Vézinet F, Descamps D
Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients.
The Journal of Antimicrobial Chemotherapy 2012, 67, 1459-1461.

2011

Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chêne G, Storto A, Collin G, Bénard A, Damond F, Mouscadet JF, Brun-Vézinet F, Descamps D, FAH2C(C0V2
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.
Antimicrobial Agents and Chemotherapy 2011, 55, 1293-1295.

Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, Mouscadet JF, Campa P, Chêne G, Brun-Vézinet F, Descamps D, FAH2C(C0
Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
Antiviral Therapy 2011, 16, 937-940.

2010

Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, Chêne G, Nie T, Schinazi R, Brun-Vézinet F, Descamps D, FAH2C(C0V2
In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.
AIDS (London, England) 2010, 24, 2753-2755.